EluSys Therapeutics Bolsters Scientific Team

Company Adds Pharmaceutical Veteran to Lead R&D Division



Apr 30, 2001, 01:00 ET from EluSys Therapeutics, Inc.

    PINE BROOK, N.J., April 30 /PRNewswire/ -- EluSys Therapeutics, Inc., a
 biopharmaceutical company focused on treatments for blood-borne diseases,
 announced today that pharmaceutical veteran George Spitalny, Ph.D., has joined
 the company as vice president of research and development.
     "George Spitalny has extensive leadership experience in pharmaceutical
 research and development," said Stephen Sudovar, president and CEO of EluSys.
 "I anticipate that he will invigorate our scientific program and move it
 forward in exciting ways."
 
     George Spitalny, Ph.D.
     Dr. Spitalny is a 25-year veteran of pharmaceutical and academic research.
 Previously, he was president of Select Therapeutics (Canada), Inc., which
 specialized in developing treatments for cancer, bacterial and certain
 metabolic diseases. Dr. Spitalny served as vice president of research and
 development and then chief scientific officer at TargeTech, Inc., where he
 organized the company's general operations, business goals and scientific
 direction.
     From 1983 to 1990, Dr. Spitalny was director of immunology at
 Bristol-Myers Squibb Co. (BMS), where his research efforts led to the
 discovery of two compounds (a drug for organ transplantation and a monoclonal
 antibody conjugate for cancer) that progressed to clinical trials. Dr.
 Spitalny also spent a decade in academic research, first at New York
 University School of Medicine and then at the Trudeau Institute in Saranac
 Lake, NY.
     "The potential applications of the Heteropolymer System EluSys is
 developing are very broad and exciting," commented Dr. Spitalny. "I look
 forward to directing the research of such a versatile and promising
 technology."
 
     The Heteropolymer System:  "Biological Double-Sided Tape"
     The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
 technology designed to enable the body to use its own red blood cells to
 efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
 and autoantibodies. The HP System uses a proprietary bi-specific monoclonal
 antibody (the Heteropolymer) which binds the target pathogen to red blood
 cells, like a piece of biological double-sided tape. The red blood cells carry
 the Heteropolymer-pathogen complex to the liver, where it is destroyed.
     The HP System has been studied against ten different model or actual
 pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
 (toxin) and autoantibodies involved in the autoimmune diseases myasthenia
 gravis and lupus.
     Experiments show that the HP System can clear even substantial levels of a
 variety of pathogens and autoantibodies from the bloodstream of nonhuman
 primates within an hour. Other experiments have demonstrated that EluSys'
 Heteropolymers may prevent pathogens from ever reaching appreciable
 concentrations in the blood when injected before exposure.
 
     About EluSys
     EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing treatments for a variety of blood-borne diseases.
 EluSys' patented monoclonal antibody-based technology, the Heteropolymer
 ("HP") System, may offer a significant advance in the management and treatment
 of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
 effectiveness of the body's own natural defense mechanisms to remove such
 pathogens from the blood and destroy them. EluSys recently signed a research
 agreement with the U.S. Army Medical Research Institute of Infectious Diseases
 (USAMRIID) to develop treatments for anthrax and other potential biowarfare
 agents. Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
 Additional information about EluSys, the HP technology and senior management
 can be found at http://www.EluSys.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X02143418
 
 

SOURCE EluSys Therapeutics, Inc.
    PINE BROOK, N.J., April 30 /PRNewswire/ -- EluSys Therapeutics, Inc., a
 biopharmaceutical company focused on treatments for blood-borne diseases,
 announced today that pharmaceutical veteran George Spitalny, Ph.D., has joined
 the company as vice president of research and development.
     "George Spitalny has extensive leadership experience in pharmaceutical
 research and development," said Stephen Sudovar, president and CEO of EluSys.
 "I anticipate that he will invigorate our scientific program and move it
 forward in exciting ways."
 
     George Spitalny, Ph.D.
     Dr. Spitalny is a 25-year veteran of pharmaceutical and academic research.
 Previously, he was president of Select Therapeutics (Canada), Inc., which
 specialized in developing treatments for cancer, bacterial and certain
 metabolic diseases. Dr. Spitalny served as vice president of research and
 development and then chief scientific officer at TargeTech, Inc., where he
 organized the company's general operations, business goals and scientific
 direction.
     From 1983 to 1990, Dr. Spitalny was director of immunology at
 Bristol-Myers Squibb Co. (BMS), where his research efforts led to the
 discovery of two compounds (a drug for organ transplantation and a monoclonal
 antibody conjugate for cancer) that progressed to clinical trials. Dr.
 Spitalny also spent a decade in academic research, first at New York
 University School of Medicine and then at the Trudeau Institute in Saranac
 Lake, NY.
     "The potential applications of the Heteropolymer System EluSys is
 developing are very broad and exciting," commented Dr. Spitalny. "I look
 forward to directing the research of such a versatile and promising
 technology."
 
     The Heteropolymer System:  "Biological Double-Sided Tape"
     The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
 technology designed to enable the body to use its own red blood cells to
 efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
 and autoantibodies. The HP System uses a proprietary bi-specific monoclonal
 antibody (the Heteropolymer) which binds the target pathogen to red blood
 cells, like a piece of biological double-sided tape. The red blood cells carry
 the Heteropolymer-pathogen complex to the liver, where it is destroyed.
     The HP System has been studied against ten different model or actual
 pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
 (toxin) and autoantibodies involved in the autoimmune diseases myasthenia
 gravis and lupus.
     Experiments show that the HP System can clear even substantial levels of a
 variety of pathogens and autoantibodies from the bloodstream of nonhuman
 primates within an hour. Other experiments have demonstrated that EluSys'
 Heteropolymers may prevent pathogens from ever reaching appreciable
 concentrations in the blood when injected before exposure.
 
     About EluSys
     EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
 focused on developing treatments for a variety of blood-borne diseases.
 EluSys' patented monoclonal antibody-based technology, the Heteropolymer
 ("HP") System, may offer a significant advance in the management and treatment
 of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
 effectiveness of the body's own natural defense mechanisms to remove such
 pathogens from the blood and destroy them. EluSys recently signed a research
 agreement with the U.S. Army Medical Research Institute of Infectious Diseases
 (USAMRIID) to develop treatments for anthrax and other potential biowarfare
 agents. Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
 Additional information about EluSys, the HP technology and senior management
 can be found at http://www.EluSys.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X02143418
 
 SOURCE  EluSys Therapeutics, Inc.